sexta-feira, 13 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 13, 2026

Federal Realty signals near 6% Core FFO growth target for 2026 while advancing residential development pipeline

View original at seekingalpha.com
Federal Realty signals near 6% Core FFO growth target for 2026 while advancing residential development pipeline Earnings Call Insights: Federal Realty Investment Trust (FRT) Q4 2025 MANAGEMENT VIEW * CEO Donald Wood highlighted a "strong quarter, strong year, strong 2026 guidance, 6.4% bottom line FFO growth in the qua…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • 601,000 feet of comparable deals done in the quarter at 12% rollover and 2.3 million feet of comparable deals done for the year at 15% rollover, an incremental $11 million of new rent is under contract

    80% confidence
  • Quarters like this fourth and in fact, all of 2025 increase my confidence of our ability to do so

    80% confidence
  • It's a little too early to kind of forecast how much we'll be able to buy this year

    80% confidence
  • Temporary anchor turnover resulting in 75 basis point drag of comparable POI in 2026

    80% confidence
  • Acquisitions achieved initial yield in low 7% range with targeted unlevered IRRs approaching 9%

    80% confidence
  • Strong quarter, strong year, strong 2026 guidance, 6.4% bottom line FFO growth in the quarter, 4.3% for the year and guidance close to 6% at the midpoint for 2026

    80% confidence
  • Strong rent spreads are broad-based and sustainable with continued high demand and limited supply

    80% confidence
  • We're able to underwrite the new development pipeline is somewhere between 6.5% and 7% on most of them

    80% confidence
  • Result was slightly below guidance midpoint due to noncash charge related to Saks bankruptcy

    80% confidence
  • California is going to be our largest source of growth for the next few years given the backlog of leasing and development activity

    80% confidence
  • You can count on us managing tax efficiently through the dividend and sales of gains and 1031

    80% confidence
  • There is probably another $400 million or $500 million of residential product that could be monetized with cap rates at 5% or lower

    80% confidence
  • In 2025, our leasing platform achieved record-breaking volume, delivering the highest annual square footage leased in company history, alongside the strongest comparable rent spreads achieved in over a decade

    80% confidence
  • Our FFO per share of $1.84 for the fourth quarter reflects 6.4% growth versus last year and highlights a really strong underlying quarter operationally

    80% confidence
  • Portfolio ended the year 96.6% leased and 94.5% occupied

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,577 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Federal Realty signals near 6% Core FFO growth target for 2026 while advancing residential development pipeline — Source | Via News | pt.VIA.NEWS